Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

Illumina, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DATASET GROWS TO MORE THAN 312,000 WHOLE GENOMES WITH LONGITUDINAL CLINICAL DATA GSK IS ONE OF THE FIRST TO LEAD A FURTHER EXPANSION OF 50,000 WHOLE GENOMES PAIRED WITH PROTEOMIC DATA  SAN DIEGO, MARCH 5, 2026 /PRNEWSWIRE/ -- ILLUMINA, INC. (NASDAQ: ILMN), ANDNASHVILLE BIOSCIENCES, LLC (NASHBIO), TODAY ANNOUNCED TWO ADVANCEMENTS IN SCALE AND DEPTH OF THEALLIANCE FOR GENOMIC DISCOVERY(AGD OR THE ALLIANCE). WITH THE ADDITION OF REGENERON GENETICS CENTER (RGC) AS THE TENTH MEMBER, THE ALLIANCE CAN EXPAND THE CORE DATASET TO 312,000 WHOLE GENOMES.

ALLIANCE FOR GENOMIC DISCOVERY EXPANDS WITH REGENERON GENETICS CENTER MEMBERSHIP AND NEW PROTEOMICS DATA OFFERING

INCREASED ADOPTION OF CLINICAL WHOLE-GENOME SEQUENCING IS ADVANCING DIAGNOSTICS FOR RARE DISEASES, WHICH AFFECT 15 MILLION AMERICAN CHILDREN SAN DIEGO, FEB. 27, 2026 /PRNEWSWIRE/ -- ILLUMINA, INC. (NASDAQ: ILMN) TODAY ANNOUNCED THAT ILLUMINA LABORATORY SERVICES, ILLUMINA'S CLIA-CERTIFIED LABORATORY, IS PROVIDING CLINICAL SEQUENCING AND INTERPRETATION SERVICES TO THE NEW DIAGNOSTIC LAB AT FLORIDA INSTITUTE FOR PEDIATRIC RARE DISEASES (IPRD) AT FLORIDA STATE UNIVERSITY (FSU) COLLEGE OF MEDICINE, FURTHER DRIVING INNOVATION IN DIAGNOSTICS AND TREATMENTS FOR RARE DISEASES. "AN ESTIMATED 30 MILLION PEOPLE ACROSS THE COUNTRY ARE LIVING WITH A RARE DISEASE TODAY AND CLINICAL WHOLE-GENOME TESTING PROVIDES A TRANSFORMATIVE OPPORTUNITY TO END THE DIAGNOSTIC ODYSSEY FOR PATIENTS," SAID ERIC GREEN, MD, PHD, CHIEF MEDICAL OFFICER OF ILLUMINA.

ILLUMINA WHOLE-GENOME SEQUENCING TECHNOLOGY TO ACCELERATE RARE DISEASE TESTING IN FLORIDA

SAN JOSE, CALIF.--(BUSINESS WIRE)-- #NGS--TAKARA BIO USA COLLABORATES WITH ILLUMINA ON A SINGLE-CELL-RESOLUTION SPATIAL MAPPING WORKFLOW, PRESENTED AT AGBT 2026.

TAKARA BIO USA, INC. COLLABORATES WITH ILLUMINA ON SPATIAL TRANSCRIPTOMICS WORKFLOW, DETAILS PRESENTED AT AGBT 2026

AT AGBT, RESEARCHERS REVEAL NEW FINDINGS FROM STUDIES LEVERAGING ILLUMINA'S MULTIOMICS SOLUTIONS SAN DIEGO, FEB. 25, 2026 /PRNEWSWIRE/ -- ILLUMINA, INC. (NASDAQ: ILMN) TODAY ANNOUNCED NEW CUSTOMER BREAKTHROUGHS IN ONCOLOGY POWERED BY ILLUMINA'S SPATIAL TRANSCRIPTOMICS, 5-BASE SEQUENCING, AND PROTEOMICS TECHNOLOGIES. THE ABILITY TO COMBINE MORE THAN ONE OMIC INSIGHT REVEALS UNPRECEDENTED BIOLOGICAL DEPTH AND KNOWLEDGE, ALL OF WHICH IS STREAMLINED BY ILLUMINA CONNECTED MULTIOMICS FOR MULTIMODAL DATA ANALYSIS.

ILLUMINA PARTNERS GO BEYOND THE GENOME, DRIVING CANCER BREAKTHROUGHS USING SPATIAL TRANSCRIPTOMICS, EPIGENOMICS, AND PROTEOMICS

TRUPATH GENOME OFFERS MORE COMPLETE GENOME, WITH THE SIMPLEST SAMPLE TO SEQUENCER WORKFLOW DATA PRESENTED AT AGBT DEMONSTRATES TRUPATH GENOME'S ACCURACY IN DETECTING RARE GENETIC DISEASE BROAD CLINICAL LABS IS AMONG FIRST TO ADOPT PRODUCT, WHICH WAS PREVIOUSLY KNOWN AS "CONSTELLATION MAPPED READ TECHNOLOGY" SAN DIEGO, FEB. 24, 2026 /PRNEWSWIRE/ --ILLUMINA, INC. (NASDAQ: ILMN) TODAY ANNOUNCED THE LAUNCH OF TRUPATH GENOME, SETTING A NEW STANDARD FOR HIGH-QUALITY, COMPREHENSIVE WHOLE GENOME INSIGHTS FOR GENETIC DISEASE. TRUPATH GENOME HAS BEEN FOUND TO DELIVER UNPARALLELED ACCURACY AND RESOLUTIONEVEN ACROSS SO-CALLED "DARK REGIONS" OF THE GENOMEPROVIDING RESEARCHERS WITH A MORE COMPLETE PICTURE OF GENOMIC ALTERATIONS IMPLICATED IN GENETIC DISEASE.

ILLUMINA LAUNCHES TRUPATH GENOME, SETTING A NEW STANDARD IN GENOMIC INSIGHT

40% INCREASE IN OUTPUT TO 35 BILLION READS, UP TO Q70 QUALITY SCORES, IMPROVED TURNAROUND TIME, AND STAGGERED STARTS ARE AMONG THE UPDATES TO BE ROLLED OUT ON ALL NOVAS EQ X SYSTEMS , ADVANCING PRECISION MEDICINE AND DELIVERINGCOMPOUNDED VALUE FOR NOVASEQ X CUSTOMERS SAN DIEGO, FEB. 23, 2026 /PRNEWSWIRE/ -- ILLUMINA, INC. (NASDAQ: ILMN) TODAY UNVEILED AN 18-MONTH ROADMAP OF INNOVATIONS THAT ENHANCE THE POWER AND VALUE OF THE NOVASEQ X SYSTEM. UPDATES INCLUDE TECHNOLOGY THAT WILL DELIVER UP TO A Q70 QUALITY SCORE FOR THE FIRST TIME, ALONG WITH 30% INCREASED SPEED AND OUTPUT UP TO 35 BILLION READS (35B).

ILLUMINA UNVEILS ROADMAP OF GROUNDBREAKING NOVASEQ X ADVANCEMENTS IN DATA QUALITY, OUTPUT, SPEED, AND FLEXIBILITY

SAN DIEGO, FEB. 17, 2026 /PRNEWSWIRE/ -- ILLUMINA, INC. (NASDAQ: ILMN) TODAY ANNOUNCED THAT MEMBERS OF ITS MANAGEMENT TEAM WILL PARTICIPATE AT THE FOLLOWING INVESTOR CONFERENCE: UPCOMING INVESTOR CONFERENCE TDCOWEN 46TH ANNUAL HEALTH CARE CONFERENCE 2026 ON MARCH 3, 2026 THE FIRESIDE CHAT IS SCHEDULED FOR 12:10PM PT (3:10PM ET). THE WEBCAST CAN BE ACCESSED THROUGH THE EVENTS & PRESENTATIONS SECTION OF ILLUMINA'S WEBSITE AT INVESTOR.ILLUMINA.COM.

ILLUMINA TO WEBCAST UPCOMING INVESTOR CONFERENCE

FOURTH QUARTER 2025 RESULTS: REVENUE OF $1.16 BILLION, UP 5% FROM Q4 2024 (UP 4% ON A CONSTANT CURRENCY BASIS) EX-CHINA REVENUE OF $1.10 BILLION, UP 8% FROM Q4 2024 (UP 7% ON A CONSTANT CURRENCY BASIS) GAAP OPERATING MARGIN OF 17.4% AND NON-GAAP OPERATING MARGIN OF 23.7% GAAP DILUTED EPS OF $2.16 AND NON-GAAP DILUTED EPS OF $1.35 FISCAL YEAR 2025 RESULTS: REVENUE OF $4.34 BILLION, FLAT COMPARED TO 2024 ON BOTH A REPORTED AND CONSTANT CURRENCY BASIS EX-CHINA REVENUE OF $4.10 BILLION, UP 2% FROM 2024 ON BOTH A REPORTED AND CONSTANT CURRENCY BASIS GAAP OPERATING MARGIN OF 18.6% AND NON-GAAP OPERATING MARGIN OF 23.1% GAAP DILUTED EPS OF $5.45 AND NON-GAAP DILUTED EPS OF $4.84 FISCAL YEAR 2026 GUIDANCE: FOR FISCAL YEAR 2026, WE EXPECT: TOTAL COMPANY REVENUE OF $4.5 BILLION TO $4.6 BILLION, REPRESENTING GROWTH OF 4% - 6% ON A REPORTED BASIS, INCLUDING A 1.5% - 2.0% BENEFIT FROM THE RECENTLY CLOSED SOMALOGIC ACQUISITION EX-CHINA ORGANIC REVENUE GROWTH OF 2% - 4%, WHICH EXCLUDES CURRENCY AND ACQUISITION IMPACTS NON-GAAP OPERATING MARGIN IN THE RANGE OF 23.3% - 23.5%, INCLUDING A NEGATIVE IMPACT OF 100BPS FROM THE SOMALOGIC ACQUISITION NON-GAAP DILUTED EPS IN THE RANGE OF $5.05 - $5.20, INCLUDING $0.18 IN DILUTION FROM THE SOMALOGIC ACQUISITION SAN DIEGO, FEB. 5, 2026 /PRNEWSWIRE/ -- ILLUMINA, INC. (NASDAQ: ILMN) ("ILLUMINA" OR THE "COMPANY") TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR 2025. "THE ILLUMINA TEAM DELIVERED A STRONG FINISH TO 2025, MARKING A RETURN TO GROWTH THROUGH DISCIPLINED EXECUTION AGAINST OUR STRATEGY," SAID JACOB THAYSEN, CHIEF EXECUTIVE OFFICER OF ILLUMINA.

ILLUMINA REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FISCAL YEAR 2025

ILLUMINA WILL SEQUENCE UP TO 4,000 UNIQUE INDIVIDUAL ANIMALS ACROSS 1,300 SPECIES, UNLOCK GENOMIC INSIGHTS FROM 50-YEAR-OLD BIOLOGICAL SAMPLES SEQUENCING CONNECTS DECADES OF PRESERVED BIODIVERSITY WITH THE LATEST MULTIOMIC TECHNOLOGIES SAN DIEGO, FEB. 3, 2026 /PRNEWSWIRE/ -- ILLUMINA, INC.(NASDAQ: ILMN) TODAY ANNOUNCED A SEQUENCING AGREEMENT WITH THE SAN DIEGO ZOO WILDLIFE ALLIANCE(SDZWA)'S FROZEN ZOO. THE 50-YEAR-OLD BIOBANK IS THE WORLD'S MOST COMPREHENSIVE AND DIVERSE COLLECTION OF LIVING CELLS FROM THREATENED AND ENDANGERED SPECIES ACROSS THE ANIMAL KINGDOM.

ILLUMINA AND THE SAN DIEGO ZOO WILDLIFE ALLIANCE PARTNER TO SEQUENCE THE FROZEN ZOO, SUPPORTING CRITICAL CONSERVATION GENETICS EFFORTS GLOBALLY

DEEPLY EXPANDS LEADERSHIP IN PROTEOMICS AND MULTIOMICS COMBINED CAPABILITIES BRING HIGH SCALABILITY, FLEXIBILITY,AND AFFORDABILITY INTO PROTEIN ANALYSIS COMBINATION LEVERAGES SOMASCAN WITH ILLUMINA'S NGS ECOSYSTEM, DRAGEN SOFTWARE, AND ILLUMINA CONNECTED MULTIOMICS TO RAPIDLY TRANSFORM INSIGHTS INTO DISCOVERIES SAN DIEGO, JAN. 30, 2026 /PRNEWSWIRE/ -- ILLUMINA, INC. (NASDAQ: ILMN) TODAY ANNOUNCED THAT IT HAS COMPLETED ITS ACQUISITION OF SOMALOGIC, A LEADER IN DATA-DRIVEN PROTEOMICS TECHNOLOGY. THE HIGHLY COMPLEMENTARY PROTEOMICS CAPABILITIES EXPAND ILLUMINA'S MULTIOMICS PORTFOLIO, STRENGTHENING CUSTOMER ACCESS TO PROTEOMIC INSIGHTS AT SCALE TO HELP DRIVE FASTER DRUG DISCOVERY AND POSITIVELY IMPACT HEALTH CARE.

ILLUMINA COMPLETES ACQUISITION OF SOMALOGIC

THE FDA-APPROVED COMPREHENSIVE GENOMIC PROFILING TEST WILL BE REIMBURSED AT A RATE OF $2,989.55 PER TEST, HELPING TO ADVANCE ADOPTION IN THE US HEALTHCARE SYSTEM SAN DIEGO, JAN. 20, 2026 /PRNEWSWIRE/ -- ILLUMINA, INC. (NASDAQ: ILMN) TODAY ANNOUNCED THAT REIMBURSEMENT HAS BEEN GRANTED FOR ITS FDA-APPROVED IN VITRO DIAGNOSTIC (IVD) TRUSIGHT ONCOLOGY (TSO) COMPREHENSIVE TEST. THE REIMBURSEMENT DECISION FROM THE CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) WILL EXPAND ACCESS TO COMPREHENSIVE GENOMIC PROFILING (CGP) AND THE GROWING ROLE OF PERSONALIZED GENOMICS IN ONCOLOGY CARE.

ILLUMINA SECURES CMS REIMBURSEMENT FOR TRUSIGHT ONCOLOGY COMPREHENSIVE, EXPANDING ACCESS TO PRECISION ONCOLOGY

THE ATLAS WILL ENABLE THE VALIDATION OF GENETIC TARGETS AND TRAINING OF AI MODELS AT UNPRECEDENTED SCALE SAN DIEGO, JAN. 13, 2026 /PRNEWSWIRE/ -- ILLUMINA, INC. (NASDAQ: ILMN) TODAY INTRODUCED THE WORLD'S LARGEST GENOME-WIDE GENETIC PERTURBATION DATASET, BEING BUILT TO ACCELERATE DRUG DISCOVERY THROUGH AI ACROSS THE PHARMACEUTICAL ECOSYSTEM. THE ILLUMINA BILLION CELL ATLAS IS THE FIRST TRANCHE OF ITS PROGRAM TO BUILD A 5 BILLION CELL ATLAS OVER THREE YEARS, AND WILL BE THE MOST COMPREHENSIVE MAP OF HUMAN DISEASE BIOLOGY TO DATE.

ILLUMINA INTRODUCES BILLION CELL ATLAS TO ACCELERATE AI AND DRUG DISCOVERY

SAN DIEGO, JAN. 13, 2026 /PRNEWSWIRE/ -- ILLUMINA, INC. (NASDAQ: ILMN) ("ILLUMINA" OR THE "COMPANY") TODAY ANNOUNCED UNAUDITED PRELIMINARY FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR 2025 AHEAD OF ITS PRESENTATION AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE ON JANUARY13, 2026 AT 7:30 A.M.

ILLUMINA ANNOUNCES PRELIMINARY UNAUDITED FINANCIAL RESULTS FOR FOURTH QUARTER AND FISCAL YEAR 2025

SAN DIEGO, JAN. 12, 2026 /PRNEWSWIRE/ -- ILLUMINA, INC. (NASDAQ:ILMN) ANNOUNCED TODAY THAT IT WILL ISSUE RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2025 FOLLOWING THE CLOSE OF MARKET ON THURSDAY, FEBRUARY 5, 2026. ON THE SAME DAY, AT 1:30 PM PACIFIC TIME (4:30 PM EASTERN TIME) JACOB THAYSEN, PHD, CHIEF EXECUTIVE OFFICER, AND ANKUR DHINGRA, CHIEF FINANCIAL OFFICER, WILL HOST A CONFERENCE CALL WITH ANALYSTS, INVESTORS, AND OTHER INTERESTED PARTIES TO DISCUSS FINANCIAL AND OPERATING RESULTS.

ILLUMINA TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS ON THURSDAY, FEBRUARY 5, 2026

VETERAN GENOMICS LEADER JOINS ILLUMINA TO ADVANCE GLOBAL MEDICAL STRATEGY ILLUMINA CHIEF COMMERCIAL OFFICER TO DEPART FOR ROLE AS A LIFE SCIENCE TOOLS COMPANY CEO SAN DIEGO, JAN. 8, 2026 /PRNEWSWIRE/ -- TODAY, ILLUMINA, INC. (NASDAQ: ILMN) ANNOUNCED THE APPOINTMENT OF ERIC D. GREEN, M.D.

ILLUMINA APPOINTS DR. ERIC GREEN AS CHIEF MEDICAL OFFICER

TAIPEI, TAIWAN, JAN. 08, 2026 (GLOBE NEWSWIRE) -- ILLUMINA TAIWAN BIOTECHNOLOGY CO., LTD., AND PRECISION MEDICINE ASIA, LIMITED (PREMIA), A LEADING ASIAN CANCER CLINICAL-GENOMIC SCREENING NETWORK, TODAY ANNOUNCED THE FORMATION OF A STRATEGIC PARTNERSHIP THAT WILL EXPAND ACCESS TO COMPREHENSIVE GENOMIC PROFILING (CGP) FOR ALL ELIGIBLE ONCOLOGY PATIENTS ACROSS THE CHANG GUNG MEMORIAL HOSPITAL (CGMH) SYSTEM. THIS PARTNERSHIP ALSO AIMS TO SUPPORT THE CREATION OF AN ASIA-WIDE CLINICAL-GENOMIC ONCOLOGY DATABASE TO ADVANCE PRECISION ONCOLOGY.

Illumina, Inc.

ILMN

Price

Financial Reports

No items found.

Press Releases

Illumina, Inc.

ILMN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ILMN